Factor v Leiden associated with flap loss in microsurgical breast reconstruction

Microsurgery

Volumn 31, Issue 5, 2011, Pages 409-412

  Khansa, Ibrahim ^a   Colakoglu, Salih ^a   Tomich, David C ^a   Nguyen, Minh Doan ^b   Lee, Bernard T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; HEPARIN; PROTEIN C; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BREAST RECONSTRUCTION; CASE REPORT; CLINICAL ASSESSMENT; DEEP INFERIOR EPIGASTRIC PERFORATOR FLAP; DISSECTION; FEMALE; GENE MUTATION; GENERAL ANESTHESIA; GLUTEUS MAXIMUS MUSCLE; GRAFT FAILURE; HUMAN; INTERNAL MAMMARY ARTERY; INTRADUCTAL CARCINOMA; INTRAOPERATIVE PERIOD; MASTECTOMY; MICROSURGERY; MICROSURGICAL BREAST RECONSTRUCTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; SENTINEL LYMPH NODE BIOPSY; SKIN SPARING MASTECTOMY; SUPERIOR GLUTEAL ARTERY PERFORATOR FLAP; VEIN ANASTOMOSIS;

FACTOR V; FEMALE; FREE TISSUE FLAPS; GRAFT OCCLUSION, VASCULAR; HUMANS; MAMMAPLASTY; MICROSURGERY; MIDDLE AGED; POINT MUTATION; THROMBOSIS;

EID: 79960178907     PISSN: 07381085     EISSN: 10982752     Source Type: Journal    
DOI: 10.1002/micr.20879     Document Type: Article

References (30)

1. Press RD, Bauer KA, Kujovich JL, Heit JA,. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002; 126: 1304-1318. (Pubitemid 36237281)
2. Ridker PM, Miletich JP, Hennekens CH, Buring JE,. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening. JAMA 1997; 277: 1305-1307. (Pubitemid 27194355)
3. Price DT, Ridker PM,. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective. Ann Intern Med 1997; 127: 895-903. (Pubitemid 27490627)
4. Dunn TB, Linden MA, Vercelloti GM, Gruessner RW,. Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clin Transplant 2006; 20: 132-135. (Pubitemid 43349039)
5. Izbicki G, Bairey O, Shitrit D, Lahav J, Kramer MR,. Increased thromboembolic events after lung transplantation. Chest 2006; 129: 412-416. (Pubitemid 43289863)
6. Page C, Rubin LE, Gusberg RJ, Dardik A,. Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: Importance of synergistic factors. J Vasc Surg 2005; 42: 1014-1018. (Pubitemid 41571975)
7. Miriuka SG, Langman LJ, Evrovski J, Miner SE, Kozuszko S, D'Mello N, Delgado DH, Wong BY, Ross HJ, Cole DE,. Thromboembolism in heart transplantation: Role of prothrombin G20210A and factor V Leiden. Transplantation 2005; 80: 590-594. (Pubitemid 41377743)
8. Atluri P, Raper SE,. Factor V Leiden and postoperative deep vein thrombosis in patients undergoing open Roux-en-Y gastric bypass surgery. Obes Surg 2005; 15: 561-564. (Pubitemid 40605083)
9. Donahue BS,. Factor V Leiden and perioperative risk. Anesth Analg 2004; 98: 1623-1634. (Pubitemid 38678619)
10. Blaszyk H, Bjornsson J,. Factor V Leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg 2000; 135: 1410-1413.
11. Hirshfield G, Collier JD, Brown K, Taylor C, Frick T, Baglin TP, Alexander GJ,. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transpl Surg 1998; 4: 58-61. (Pubitemid 28053312)
12. Kenner L, Schwarzl F, Moshammer H, Haas F, Hoefler G, Pierer G,. Venous thrombosis in a replanted finger with underlying factor V Leiden mutation. Br J Plast Surg 1998; 51: 57-58. (Pubitemid 28043816)
13. Handschin AE, Guggenheim M, Calcagni M, Kunzi W, Giovanoli P,. Factor V Leiden mutation and thrombotic occlusion of microsurgical anastomosis after free TRAM flap. Clin Appl Thromb Hemost 2010; 16: 199-203.
14. Warnecke IC, Kretschmer F, Bruner S, Frerichs O, Fansa H,. Hereditary thrombophilia in free microvascular flaps-A case report. Handchir Mikrochir Plast Chir 2007; 39: 220-224. (Pubitemid 46996895)
15. Vekris MD, Ovrenovits M, Dova L, Beris AE, Soucacos PN, Kolaitis N, Vartholomatos G,. Free functional muscle transfer failure and thrombophilic gene mutations as a potential risk factor: A case report. Microsurgery 2007; 27: 88-90. (Pubitemid 46411433)
16. Davison SP, Kessler CM, Al-Attar A,. Microvascular free flap failure caused by unrecognized hypercoagulability. Plast Reconstr Surg 2009; 124: 490-495.
17. Hidalgo DA, Jones CS,. The role of emergent exploration in free-tissue transfer: A review of 150 consecutive cases. Plast Reconstr Surg 1990; 86: 492-498. (Pubitemid 20266665)
18. Bui DT, Cordeiro PG, Hu QY, Disa JJ, Pusic A, Mehrara BJ,. Free flap reexploration: Indications, treatment, and outcomes in 1193 free flaps. Plast Reconstr Surg 2007; 119: 2092-2100. (Pubitemid 46847103)
19. Tran NV, Buchel EW, Convery PA,. Microvascular complications of DIEP flaps. Plast Reconstr Surg 2007; 119: 1397-1405. (Pubitemid 46559106)
20. Bar-Meir ED, Yueh JH, Tobias AM, Lee BT,. Autologous fat grafting: A technique for stabilization of the microvascular pedicle in DIEP flap reconstruction. Microsurgery 2008; 28: 495-498.
21. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ,. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-1148. (Pubitemid 26176993)
22. Hellgren M, Svensson PJ, Dahlback B,. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-213.
23. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR,. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457. (Pubitemid 24351698)
24. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vanderbroucke JP,. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defect. Arch Intern Med 2000; 160: 49-52. (Pubitemid 30040972)
25. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A,. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. BMJ 1997; 314: 796-800.
26. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S,. Postmenopausal hormonal therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000; 132: 689-696. (Pubitemid 30244167)
27. Meier CR, Jick H,. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608-612. (Pubitemid 28270919)
28. Weitz IC, Israel VK, Liebman HA,. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-2027. (Pubitemid 27200388)
29. Arnljots B, Söderström T, Svensson H,. No correlation between activated protein C resistance and free flap failures in 100 consecutive patients. Plast Reconstr Surg 1998; 101: 1850-1853. (Pubitemid 28262313)
30. Ouriel K, Green RM, De Weese JA, Cimino C,. Activated protein C resistance: Prevalence and implications in peripheral vascular disease. J Vasc Surg 1996; 23: 46-51.